Substance P markedly ameliorates scopolamine-induced impairment of spontaneous alternation performance in the mouse.
We investigated the effects of intracerebroventricular injection of substance P (SP) on the scopolamine (1 mg/kg)-induced impairment of spontaneous alternation performance in the mouse. SP (0.001-3 micrograms) alone did not influence either spontaneous alternation performance or total arm entries. Scopolamine (1 mg/kg) impaired spontaneous alternation performance accompanied by an increment in total arm entries. In contrast, SP (0.01-1 micrograms) significantly improved the scopolamine (1 mg/kg)-induced impairment of spontaneous alternation performance without influencing the scopolamine (1 mg/kg)-induced increase in total arm entries. The effects of SP (0.1 micrograms) on the scopolamine (1 mg/kg)-induced impairment of spontaneous alternation performance were almost completely reversed by pretreatment with WIN 62577 (1 mg/kg), a tachykinin NK-1 receptor antagonist. These results suggest that SP improves the scopolamine-induced impairment of spontaneous alternation performance through the mediation of tachykinin NK-1 receptors.
Ukai
M
M
Department of Chemical Pharmacology, Faculty of Pharmaceutical Sciences, Meijo University, Nagoya, Japan.
Shinkai
N
N
Ohashi
K
K
Kameyama
T
T
D000736:Androstenes / Q000494:pharmacology; D000818:Animals; D001562:Benzimidazoles / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D007859:Learning Disabilities; D008297:Male; D051379:Mice; D064729:Neurokinin-1 Receptor Antagonists; D012601:Scopolamine / Q000494:pharmacology; D013373:Substance P / Q000494:pharmacology*
D000736:Androstenes; D001562:Benzimidazoles; D064729:Neurokinin-1 Receptor Antagonists; C086110:WIN 62577; D013373:Substance P; D012601:Scopolamine